期刊
LEUKEMIA & LYMPHOMA
卷 57, 期 7, 页码 1517-1526出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2016.1185783
关键词
Molecular genetics; myeloid leukemias and dysplasias; stem and primitive progenitor cells
资金
- NCI NIH HHS [L30 CA153312, K08 CA188529, K08 CA160647] Funding Source: Medline
This review is based on the deliberations at the 5th John Goldman Colloquium held in Estoril on 2nd October 2015 and the 9th post-ASH International Workshop on chronic myeloid leukemia (CML) and BCR-ABL1-negative myeloproliferative neoplasms (MPN) which took place on the 10th-11th December 2014, immediately following the 56th American Society of Hematology Annual Meeting. It has been updated since and summarizes the most recent advances in the biology and therapy of these diseases, in particular updates of genetics of MPN, novel insights from mouse MPN models, targeting CML stem cells and its niche; clinical advances include updates on JAK2 inhibitors and other therapeutic approaches to BCR-ABL1-negative MPNs, the use of alpha interferons, updates on tyrosine kinase inhibitors (TKI) randomized trials in CML, TKI cessation studies, and optimal monitoring strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据